Browse the evidence

Adipose-derived mesenchymal stem cell (ADMSC) therapy reduces body weight and improves metabolic complications (diabetes, NAFLD) in animal models, though clinical efficacy remains controversial due to low cell survival rates.

ADMSC therapy shows promise in reducing weight and improving metabolic health in animal studies, but it is not yet a standard or proven treatment for humans. Clinical efficacy is controversial, and cell survival after transplantation is low. Patients should not expect this to be a current standard of care.

Geroscience aims to compress the period of morbidity by targeting the fundamental biological mechanisms of aging, rather than treating individual age-related diseases in isolation.

This paper outlines a research strategy, not a direct lifestyle intervention. However, the implication for an individual is that healthspan (the period of life spent in good health) is a distinct and measurable goal from lifespan. Supporting geroscience research involves advocating for and participating in studies that target fundamental aging processes (like cellular senescence or metabolic regulation) rather than just managing symptoms of single diseases as they appear.

Saturated fats do not cause cardiovascular disease; instead, coronary heart disease is driven by silent inflammation resulting from insufficient omega-3s, excessive omega-6s, and high fructose intake.

Stop fearing natural saturated fats like those in butter and meat. Instead, focus on reducing processed foods, sugar (especially fructose), and industrial trans fats. Ensure you get enough omega-3s from fish or supplements to manage inflammation, as this is the true driver of heart disease, not the saturated fat itself.

Palmitic acid is only harmful when produced endogenously via de novo lipogenesis from excess fructose; dietary palmitic acid is not the primary culprit for metabolic issues.

You don't need to strictly avoid dietary palmitic acid (found in meat, butter, palm oil). The real danger is consuming too much fructose (sugar, juice), which your liver converts into palmitic acid, causing inflammation. Reduce sugar, and your body handles saturated fats much better.

GLP-1 receptor agonists (GLP-1RAs) exert immunoregulatory effects by promoting the polarization of macrophages and microglia from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, thereby reducing neuroinflammation and systemic inflammatory markers.

If you are using a GLP-1RA (like semaglutide or liraglutide) for diabetes or weight loss, understand that it may also be helping to lower systemic inflammation by shifting your immune cells toward a less inflammatory state. This is not just a side effect but a direct mechanism of action on your immune system.

GLP-1RAs modulate T cell differentiation by reducing the proportion of pro-inflammatory Th17 cells and increasing regulatory T cells (Tregs), thereby improving immune tolerance and reducing inflammation in conditions like psoriasis and colitis.

For those with autoimmune conditions, GLP-1RAs may help rebalance your immune system by reducing inflammatory T cells and boosting regulatory ones. This could potentially complement standard treatments by addressing the underlying immune imbalance.

GLP-1RAs reduce innate allergic inflammation and eosinophilia by inhibiting the activity of Group 2 Innate Lymphoid Cells (ILC2s) and reducing the production of type 2 cytokines (IL-5, IL-13).

If you have allergic asthma, GLP-1RAs might help reduce the specific allergic inflammation driven by innate immune cells, potentially easing symptoms beyond just metabolic benefits.

The MAPK signaling pathway (specifically ERK, JNK, and p38) plays a complex, context-dependent role in obesity, regulating appetite, adipogenesis, and insulin resistance, with effects varying between in vitro and in vivo models.

Obesity involves complex signaling networks like MAPK that regulate fat storage and insulin sensitivity. The fact that these pathways have conflicting effects in different contexts explains why single-target interventions often fail and why obesity is a heterogeneous disorder.

GDF15, a member of the TGF-β superfamily, acts as a central regulator of appetite and a potential treatment for obesity by reducing food intake and stimulating lipolysis.

GDF15 is a hormone that reduces food intake and increases fat burning. Research suggests it could be a future treatment for obesity, offering a different mechanism from current drugs.

Ketogenic diets may have anti-cancer effects by exploiting the Warburg effect, starving cancer cells of glucose and making them more vulnerable to chemotherapy and radiation.

KD is being studied as an adjuvant therapy for cancer to starve cells of glucose. Consult your oncologist before trying this.

Sustained caloric restriction of 25% below ad libitum intake over two years induces metabolic adaptation, specifically reducing resting metabolic rate and core body temperature, in nonobese humans.

To potentially slow aging markers, non-obese adults may attempt a sustained 25% reduction in daily calories. This requires significant behavioral support and monitoring to maintain, as it is a substantial deficit compared to normal eating habits.

Adiposity causes coronary heart disease (CHD), although the causal effect size is smaller and less statistically robust than for heart failure or stroke in this specific analysis.

Managing your weight can help reduce your risk of coronary heart disease. While the link might be less direct than for heart failure, reducing adiposity can lower the risk of atherosclerosis and related heart issues. Consult with a healthcare provider for personalized advice.

Fish oil supplementation does not significantly alter resting metabolic rate (RMR) or respiratory exchange ratio (RER) in healthy adults over 6 weeks.

Do not expect fish oil to significantly increase your resting metabolic rate. Its benefits for body composition likely come from other mechanisms, such as lowering cortisol.

Accumulation of Persistent Organic Pollutants (POPs) in adipose tissue is associated with a metabolically unhealthy obesity phenotype, suggesting that environmental toxins may drive metabolic dysfunction and inflammation.

Reducing body fat may help lower your body burden of environmental toxins stored in adipose tissue. Prioritize a diet low in highly processed foods and high-fat animal products, which can be sources of certain POPs, and maintain a healthy weight to minimize the reservoir for these metabolic disruptors.

The protective association of glucosamine against all-cause mortality is significantly stronger in current smokers compared to non-current smokers.

If you smoke and take glucosamine, this study suggests you might derive a greater mortality benefit than non-smokers, possibly because your body has higher inflammation to counteract. However, quitting smoking remains the most effective way to reduce mortality risk.

GLP-1-based therapies and SGLT2 inhibitors provide protective effects on the coronary microvascular compartment in diabetic patients, addressing coronary microvascular dysfunction (CMD).

If you have diabetes and signs of heart issues like chest pain or shortnessess of breath without blocked arteries (CMD), ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs are increasingly recognized to protect the small blood vessels in the heart, beyond just lowering blood sugar.

Increasing energy expenditure through mitochondrial uncoupling in specific organs (like the liver) is a promising therapeutic strategy for metabolic diseases, but previous attempts with non-specific uncouplers (like DNP) failed due to severe side effects.

Current non-specific energy expenditure boosters are unsafe. However, research is focusing on organ-specific strategies (like liver-targeted uncoupling) to treat metabolic diseases safely. This is not yet a available clinical option.

Saturated fat intake increases HDL cholesterol and improves the total-to-HDL cholesterol ratio, which are robust markers of cardiovascular disease risk.

Saturated fat intake raises HDL cholesterol and improves the total-to-HDL ratio, which are important markers of heart disease risk. This suggests that focusing solely on lowering LDL may be an incomplete strategy for assessing cardiovascular health.

Long-term LCHF diet adaptation may lead to the early development of central fatigue during exercise due to elevated blood concentrations of non-esterified fatty acids (NEFA) and ammonia.

Be aware that switching to a low-carb diet might make you feel mentally tired or 'lethargic' during exercise, especially early on. This is due to changes in blood chemistry (fatty acids and ammonia) affecting your brain. This is a known potential downside of LCHF that may counteract physical benefits.

Endogenous GLP-1 secretion is stimulated by specific nutrient-sensing mechanisms in intestinal L-cells, including SGLT1 and KATP channels for carbohydrates, FFA1 and GPR119 for fats, and Pept1 and CaSR for proteins.

This paper explains the biological 'sensors' in your gut that trigger GLP-1 release when you eat carbs, fats, and proteins. While understanding these mechanisms (like SGLT1 for sugar or GPR119 for fat) is crucial for drug development, there are currently no standard dietary protocols to specifically target these receptors for therapeutic GLP-1 elevation. The paper highlights that while animal models show clear results, human applicability is still being researched.

Long-term adherence to GLP-1 receptor agonist therapy significantly reduces the risk of major adverse liver outcomes (MALO) in patients with chronic liver disease and type 2 diabetes, whereas intention-to-treat analysis shows no significant benefit due to high discontinuation rates.

If you have chronic liver disease and type 2 diabetes, GLP-1 medications (like semaglutide or liraglutide) can significantly lower your risk of serious liver complications (like cirrhosis or liver cancer) over 10 years, BUT only if you keep taking them. Half of the patients in this study stopped taking the drug, which erased the benefit in the general group. To get the liver protection, you must manage side effects and stay on the treatment long-term.

Population-wide fiscal measures, such as taxes on sugar-sweetened beverages and unhealthy foods, can reduce purchases of taxed items and prevent childhood obesity cases, though their immediate impact on population health outcomes is limited and requires sustained implementation.

Government taxes on sugary drinks and unhealthy foods can reduce their purchase, but these policies are often weakened by industry opposition. For individuals, this means these products may remain accessible, so personal choices remain critical.

Obesity is associated with altered nutrient sensing mechanisms in the gut, specifically region-dependent changes in the expression of amino acid and bitter taste receptors, which may contribute to inconsistent gut hormone fluctuations.

In obesity, the gut's ability to sense nutrients like proteins and fats changes depending on the location in the gut. This altered sensing contributes to why hormone signals (like GLP-1 or PYY) might not work as expected in obese individuals compared to lean ones.

Individuals who are lean and metabolically healthy (low BMI, low triglycerides, high HDL) experience marked elevations in LDL cholesterol when consuming a carbohydrate-restricted diet, a phenotype termed 'lean mass hyper-responder' (LMHR).

If you are lean and metabolically healthy, a low-carb diet might significantly raise your LDL cholesterol. This does not necessarily mean your heart health is worse, as your other markers (triglycerides, HDL) are likely excellent. If you are concerned, you can moderately increase carbohydrate intake (50-100g/day) to lower LDL, or continue the diet while monitoring other risk factors. Consult a doctor to interpret your full lipid profile in context.